Ingenol mebutate is a topical agent used for the treatment of actinic keratosis. Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®.
- Mechanism
- Curator reviewed
The exact mechanism of action of ingenol mebutate in actinic keratosis is unknown. It is presumed to involve primary necrosis then neutrophil-mediated inflammation and antibody-dependent cell death of residual disease cells. Additionally in early studies, PEP005 was shown to be an effective activator of PKC-delta and PKC-delta translocation into nucleus and membranes. PEP005 also downregulates the expression and activity of PKC-alpha. PEP005 induced modulation of PKCs leads to Ras/Raf/MAPK and p38 activation and AKT/PKB inhibition.
- Primary indication
- For the topical treatment of actinic keratosis.Curator reviewed · 1 structured indication
- Formula / weight
- C25H34O6 · 430.541 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2012
- Code names
- AGN 204332 · PEP-005
Resolves to
VDJHFHXMUKFKET-UXMMOKKRSA-NSMILES[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)CWhat you can answer from here — as of September 15, 2026
Which drugs share a target with Ingenol mebutate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account